

Remarks

Applicants have also respectfully requested amendment of the Specification by insertion of the paper copy of the revised Sequence Listing attached to this response (replacement sheets 1-19) into the Specification to replace the previous Sequence Listing found on pages 97-105. A computer disk containing a revised Sequence Listing was submitted on July 10, 2002 for copending application U.S.S.N. 08/182,183 and may be used for this application.

The revision to the Sequence Listing provides a separate listing (i.e., SEQ ID NO:26) for an amino acid sequence depicted in SEQ ID NO:25. Furthermore, the revision provides a separate listing (i.e., SEQ ID NO:29) for an amino acid sequence shown in Figure 22 which was discussed separately from the nucleic acid sequence also shown in Figure 22, amino acids 1-50 of human pre-pro GDNF. The amino acid sequence of SEQ ID NO:26 and SEQ ID NO:29 is fully supported by original Figure 22.


Applicants have also requested various amendments in order to make the application conform to the revised Sequence Listing submitted herewith. Applicants further assert that no new matter is being added in order to make the application conform to the revised Sequence Listing submitted herewith.

Applicants have also requested amendment of the present Specification to correct certain inconsistencies in nomenclature or typographical errors found throughout the Specification. For instance, the Specification referred to certain polypeptide molecules both as "pre-proGDNF" and "pre-pro GDNF". The Applicants have identified occurrences of "pre-proGDNF" in the Specification and respectively request that they be changed to read "pre-pro GDNF". Because

these amendments are requested solely for the sake of consistency and/or form, Applicants assert that no new matter is introduced by these amendments to the Specification.

In addition, Applicants respectfully request that claims 1 to 25 and 27 to 74 are cancelled without prejudice prior to examination.

Respectfully submitted,

A handwritten signature in cursive script, appearing to read "Robert L. Sharp", is written over a horizontal line.

Robert L. Sharp
Attorney/Agent for Applicant(s)
Registration No.: 45,609
Phone: (805) 447-5992
Date: January 14, 2004

Please send all future correspondence to:

U.S. Patent Operations/ RLS
Dept. 4300, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799